The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4381-4386

  Podnecky, Nicole L ^a   Wuthiekanun, Vanaporn ^b   Peacock, Sharon J ^b,c   Schweizer, Herbert P ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BPEEF OPRC PROTEIN; COTRIMOXAZOLE; FOLA PROTEIN; ISBMA2 PROTEIN; MEMBRANE PROTEIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GENE INSERTION; GENE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TRANSPORT; THAILAND; TRANSCRIPTION REGULATION;

ANTI-BACTERIAL AGENTS; AUSTRALIA; BACTERIAL PROTEINS; BASE SEQUENCE; BURKHOLDERIA PSEUDOMALLEI; GENE EXPRESSION; GENES, MDR; HUMANS; MELIOIDOSIS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; TERMINATOR REGIONS, GENETIC; TETRAHYDROFOLATE DEHYDROGENASE; THAILAND; TRIMETHOPRIM; TRIMETHOPRIM RESISTANCE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84882420742     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00660-13     Document Type: Article

References (30)

1. Currie BJ, Dance DAB, Cheng AC. 2008. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1):S1-S4. doi:10.1016/S0035-9203(08)70002-6.
2. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N. Engl. J. Med. 367:1035-1044.
3. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. 2006. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat. Rev. Microbiol. 4:272-282.
4. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416.
5. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl. Trop. Dis. 4:e900. doi:10.1371/journal.pntd.0000900.
6. Limmathurotsakul D, Peacock SJ. 2011. Melioidosis: a clinical overview. Br. Med. Bull. 99:125-139.
7. Wuthiekanun V, Peacock SJ. 2006. Management of melioidosis. Expert Rev. Anti Infect. Ther. 4:445-455.
8. Schweizer HP. 2012. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol. 7:1389-1399.
9. Peacock SJ, Schweizer HP, Dance DAB, Smith TL, Gee JE, Wuthiekanun V, DeShazer D, Steinmetz I, Tan P, Currie BJ. 2008. Accidental laboratory exposure to Burkholderia pseudomallei and Burkholderia mallei. Emerg. Infect. Dis. 14:e2. doi:10.3201/eid1407.071501.
10. Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, Currie BJ, Dance D, Gee JE, Larsen J, Limmathurotsakul D, Morrow MG, Norton R, O'Mara E, Peacock SJ, Pesik N, Rogers LP, Schweizer HP, Steinmetz I, Tan G, Tan P, Wiersinga WJ, Wuthiekanun V, Smith TL. 2012. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg. Infect. Dis. 18:e2. doi:10.3201/eid1812.120638.
11. Walsh C. 2003. Antibiotics: actions, origins, resistance. ASM Press, Washington, DC.
12. Lumbiganon P, Tattawasatra U, Chetchotisakd P, Wongratanacheewin S, Thinkamrop B. 2000. Comparison between the antimicrobial susceptibility of Burkholderia pseudomallei to trimethoprim-sulfamethoxazole by standard disk diffusion method and by minimal inhibitory concentration determination. J. Med. Assoc. Thai. 83:856-860.
13. Piliouras P, Ulett GC, Ashurst-Smith C, Hirst RG, Norton RE. 2002. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int. J. Antimicrob. Agents 19:427-429.
14. Wuthiekanun V, Cheng AC, Chierakul W, Amornchai P, Limmathurotsakul D, Chaowagul W, Simpson AJ, Short JM, Wongsuvan G, Maharjan B, White NJ, Peacock SJ. 2005. Trimethoprim/ sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother. 55:1029-1031.
15. Raja NS. 2008. Cases of melioidosis in a university teaching hospital in Malaysia. J. Microbiol. Immunol. Infect. 41:174-179.
16. Paveenkittiporn W, Apisarnthanarak A, Dejsirilert S, Trakulsomboon S, Thongmali O, Sawanpanyalert P, Aswapokee N. 2009. Five-year surveillance for Burkholderia pseudomallei in Thailand from 2000 to 2004: prevalence and antimicrobial susceptibility. J. Med. Assoc. Thai. 9(Suppl 4):S46-S52.
17. Sköld O. 2001. Resistance to trimethoprim and sulfonamides. Vet. Res. 32:261-273.
18. Kumar A, Chua K-L, Schweizer HP. 2006. Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob. Agents Chemother. 50:3460-3463.
19. Biot FV, Valade E, Garnotel E, Chevalier J, Villard C, Thibault FM, Vidal DR, Pages JM. 2011. Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: proteomic and mechanistic evidence. PLoS One 6:e16892. doi:10.1371/journal.pone .0016892.
20. DeShazer D, Brett P, Carlyon R, Woods D. 1997. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J. Bacteriol. 179:2116-2125.
21. Hayden HS, Lim R, Brittnacher MJ, Sims EH, Ramage ER, Fong C, Wu Z, Crist E, Chang J, Zhou Y, Radey M, Rohmer L, Haugen E, Gillett W, Wuthiekanun V, Peacock SJ, Kaul R, Miller SI, Manoil C, Jacobs MA. 2012. Evolution of Burkholderia pseudomallei in recurrent melioidosis. PLoS One 7:e36507. doi:10.1371/journal.pone.0036507.
22. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement, CSLI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948.
24. Lopez CM, Rholl DA, Trunck LA, Schweizer HP. 2009. Versatile dualtechnology system for markerless allele replacement in Burkholderia pseudomallei. Appl. Environ. Microbiol. 75:6496-6503.
25. Choi K-H, Mima T, Casart Y, Rholl D, Kumar A, Beacham IR, Schweizer HP. 2008. Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl. Environ. Microbiol. 74:1064-1075.
26. Kumar A, Mayo M, Trunck LA, Cheng AC, Currie BJ, Schweizer HP. 2008. Expression of resistance-nodulation-cell division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from Northern Australia. Trans. R. Soc. Trop. Med. Hyg. 102(Suppl 1): S145-S151. doi:10.1016/S0035- 9203(08)70032-4.
27. Mima T, Schweizer HP. 2010. The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob. Agents Chemother. 54:3113-3120.
28. Song H, Hwang J, Yi H, Ulrich RL, Yu Y, Nierman WC, Kim HS. 2010. The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog. 6:e1000922. doi:10.1371/journal.ppat.1000922.
29. Holden MTG, Titball RW, Peacock SJ, Cerdeno-Tarraga AM, Atkins TP, Crossman LC, Pitt TL, Churcher C, Mungall KL, Bentley SD, Sebaihia M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, Simmonds M, Songsivilai S, Stevens K, Tumapa S, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PCF, Parkhill J. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl. Acad. Sci. U. S. A. 101:14240-14245.
30. Tuanyok A, Leadem BR, Auerbach RK, Beckstrom-Sternberg SM, Beckstrom-Sternberg JS, Mayo M, Wuthiekanun V, Brettin TS, Nierman WC, Peacock SJ, Currie BJ, Wagner DM, Keim P. 2008. Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics 9:566. doi: 10.1186/1471-2164-9-566.